Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.

Summary

The main objective of the study is to evaluate the efficacy and safety of maintenance therapy with hypomethylating agent and Venetoclax to improve leukemia free survival for high-risk myeloid malignancies after allogeneic hematopoietic stem cell transplantation .

Eligibility

Inclusion Criteria:

* Patients with AML or MDS and have received allogeneic hematopoietic cell transplantation;
* Patients with AML must have one of the following high-risk factors: Cytogenetics and molecular features consistent with adverse risk group by European LeukemiaNet classification for AML； require more than 2 courses of induction chemotherapy to reach complete remission； Extramedullary myeloid malignancy；≥CR2； Presence of measurable residual disease at the time of HSCT. \*
* Patients with MDS must have one of the following high-risk factors: IPSS-R scores are high-risk or very high-risk； Presence of TP53 mutation； Presence of measurable residual disease at the time of HSCT. \*
* CBC: ANC ≥ 1.0 × 10e9/L, Hb ≥ 80g/L, and PLT ≥ 50 × 10e9/L；
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

  * Presence of measurable residual disease at the time of HSCT is defined as the following: Blast percentage in bone marrow detected by flow cytometry ≥0.01%； Presence of fusion gene or mutated gene by qPCR.

Exclusion Criteria:

* Concurrent use of targeted drugs ;
* Resistant to Venetoclax before transplantation;
* Allergic to decitabine , Azacitidine or venetoclax;
* Active grade II or higher acute GVHD ;
* Active moderate or severe chronic GVHD ;
* Diseases recurrence (abnormal myeloid cells detected by flow cytometry \>0.01%, presence of WT1 or other genes, or extramedullary malignancy ), percentage of donor cells in bone marrow \<90% or graft rejection:
* CBC: ANC \< 1.0 × 10e9/L, or PLT \< 50 × 10e9/L；
* Severe organ dysfunction: Elevated Aspartate transaminase (AST) /alanine transaminase (ALT), or direct bilirubin \>3 times upper limit of normal; Creatinine clearance (Ccr)\<50mL/min or serum creatinine \>1.5 times upper limit of normal, whether hemodialysis treatment is performed;
* Active uncontrolled systemic fungal, bacterial, or viral infection
* Pregnant or lactating women;
* Other severe complications and not suitable judged by researchers.

Conditions4

Interventions2

Related trials

• A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL — German CLL Study Group
• A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) — Dizal (Jiangsu) Pharmaceutical Co., Ltd.
• A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia — Shanghai Tong Ren Hospital
• A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — AbbVie
• A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia — BeOne Medicines
• A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML — Stichting Hemato-Oncologie voor Volwassenen Nederland
• ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL — Institute of Hematology & Blood Diseases Hospital, China
• AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission — The First Affiliated Hospital of Soochow University

Browse More Trials